- Home
- EVO vs FOR Comparison
EVO vs FOR Comparison
Compare EVO & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVO
- FOR
- Stock Information
- Founded
- EVO 1993
- FOR 2005
- Country
- EVO Germany
- FOR United States
- Employees
- EVO N/A
- FOR N/A
- Industry
- EVO Biotechnology: Pharmaceutical Preparations
- FOR Real Estate
- Sector
- EVO Health Care
- FOR Finance
- Exchange
- EVO Nasdaq
- FOR Nasdaq
- Market Cap
- EVO 1.2B
- FOR 1.0B
- IPO Year
- EVO 2021
- FOR 2007
- Fundamental
- Price
- EVO $3.73
- FOR $27.07
- Analyst Decision
- EVO Buy
- FOR Strong Buy
- Analyst Count
- EVO 2
- FOR 4
- Target Price
- EVO $5.40
- FOR $30.25
- AVG Volume (30 Days)
- EVO 41.5K
- FOR 137.0K
- Earning Date
- EVO 11-05-2025
- FOR 10-28-2025
- Dividend Yield
- EVO N/A
- FOR N/A
- EPS Growth
- EVO N/A
- FOR N/A
- EPS
- EVO N/A
- FOR 3.19
- Revenue
- EVO $912,894,891.00
- FOR $1,543,300,000.00
- Revenue This Year
- EVO $0.39
- FOR $3.62
- Revenue Next Year
- EVO $9.53
- FOR $7.99
- P/E Ratio
- EVO N/A
- FOR $8.40
- Revenue Growth
- EVO N/A
- FOR 2.35
- 52 Week Low
- EVO $2.84
- FOR $18.00
- 52 Week High
- EVO $5.64
- FOR $34.82
- Technical
- Relative Strength Index (RSI)
- EVO 57.04
- FOR 49.64
- Support Level
- EVO $3.43
- FOR $27.40
- Resistance Level
- EVO $3.55
- FOR $28.25
- Average True Range (ATR)
- EVO 0.08
- FOR 0.76
- MACD
- EVO 0.05
- FOR -0.27
- Stochastic Oscillator
- EVO 90.27
- FOR 14.12
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.